Deep Genomics, a Toronto, Canada-based AI driven genetic medicine company, raised $13m in follow-on financing.
The round was co-led by Khosla Ventures with participation from True Ventures.
Founded in 2015 by Brendan Frey, CEO and scientific founder, Deep Genomics is building a biologically accurate data- and AI-driven platform that supports geneticists, molecular biologists and chemists in the development of therapies. In project Saturn, the platform will be used to search across a vast space of over 69 billion molecules and to generate a library of 1000 compounds that can be used to precisely manipulate cell biology.
This technology will enable the company to identify preclinical candidates and to advance them for clinical evaluation in collaboration with stakeholders.
Deep Genomics is a spin out of the University of Toronto. Its laboratory is located at Johnson & Johnson Innovation, JLABS, in Toronto, a 40,000 square-foot life science innovation center located in the MaRS Discovery District.
The labs provide a flexible environment for startup companies pursuing new technologies and research platforms to advance medical care.
FinSMEs
26/09/2017